Seefinish Insights Trends news knowledge Discovery

ReadR

ReadR

ReadR: Read and Share all content, headlines, news and trends results with Seefinish ReadR App.

Discover Content : Trends

Discover real-time trending topics, news headlines, twitter trends, google trends, hashtags, and content from different countries in the world.

Search Here

Navigation Tabs

Top Countries

Select Country:🌐

Worldwide 🌍 | Nigeria 🇳🇬 | South Africa 🇿🇦 | Kenya 🇰🇪 |Brazil 🇧🇷| Canada 🇨🇦 | United Kingdom 🇬🇧| United States 🇺🇸

See all other continents, locations, categories and associated headlines or trending informations here using

America:
Brazil 🇧🇷| Canada 🇨🇦 | United States 🇺🇸

Africa:
Algeria 🇩🇿 | Egypt 🇪🇬 | Ghana 🇬🇭 | Kenya 🇰🇪 |Morocco 🇲🇦| Nigeria 🇳🇬 | South Africa 🇿🇦 |

Middle East:
| Israel 🇮🇱|Saudi Arabia 🇸🇦 |Turkey 🇹🇷| Cyprus 🇨🇾 |

Europe:
Finland 🇫🇮|France 🇫🇷| Hungary 🇭🇺 |Germany 🇩🇪| Italy 🇮🇹 | Slovakia 🇸🇰 | Switzerland 🇨🇭 | United Kingdom 🇬🇧

Australia/Oceania: 🌐
Australia 🇦🇺|New Zealand 🇦🇺

Asia:
China 🇨🇳 | Japan 🇯🇵| India 🇮🇳| Malaysia 🇲🇾| Singapore 🇸🇬 |Thailand 🇹🇭 |

Show more
Show less

Headline : India to manufacture medication for diabetes, obesity under PLI by 2026: Report

Read more from the original article on here at www.firstpost.com.





Tags : #india #manufacture #medication #diabetes #obesity #under #pli #2026 #report


No. of Paragraph 14

According to market research firm IMARC Group, there are 225 million overweight people and about 80 million obese people in India. More than 11% of Indian adults over the age of 20 who participated in the study had diabetes, and 15% had pre-diabetes read more

Incentives are being planned by India in 2026 to encourage domestic production of GLP-1 medications, which are used to treat obesity and diabetes.

A report by news agency Reuters claimed that GLP-1 (glucagon-like peptide-1) medications, which were first licensed to treat diabetes, are now frequently used to treat obesity because they slow down digestion and prolong feelings of fullness in patients.

The patent on semaglutide, a GLP-1 agonist and the main component of the immensely successful diabetes and obesity medications Wegovy and Ozempic made by Danish pharmaceutical company Novo Nordisk, is scheduled to expire in India in 2026, according to industry analysts.

Read more from the original article on here at www.firstpost.com.


Related Headlines : India to manufacture medication for diabetes, obesity under PLI by 2026: Report (in Google.com):

Hello, below you have a "Web" tab to read more content and an "Image" tab to get related pictures

Example : Trends, Country, News, Jobs, Scholarships, Investment, Business, Politics, Adverts, Fashion, Events, Technology and more.